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Background: T2-weighted imaging (T2-WI) information has been used in a qualitative 
manner in the assessment of prostate cancer. Quantitative derivatives (T2 relaxation 
time) can be generated from T2-WI.  These outputs may be useful in helping to 
discriminate clinically significant prostate cancer from background signal.    
Purpose/Hypothesis: To investigate changes in quantitative T2 parameters in lesions 
and non-cancerous tissue of men on active surveillance for prostate cancer taking 
dutasteride 0.5 mg or placebo daily for six months. 
Study type: Retrospective 
Population/Subjects: Forty men randomized to 6 months of daily dutasteride (n=20) 
or placebo (n=20). 
Field strength/Sequence: Multiparametric 3T MRI at baseline and 6 months. This 
included a multi-echo MR sequence for quantification of the T2 relaxation times, in three 
regions of interest [index lesion, non-cancerous peripheral (PZ) and transitional (TZ) 
zones]. A synthetic signal contrast (T2Q contrast) between lesion and non-cancerous 
tissue was assessed using quantitative T2 values. Signal contrast was calculated using 
the T2-weighted sequence (T2W contrast).  
Assessment: Two radiologists reviewed the scans in consensus according to Prostate 
Imaging Reporting and Data System (PI-RADS v.2) guidelines. 
Statistical tests: Wilcoxon and Mann-Whitney U tests, Spearman’s correlation. 
Results:  When compared to non-cancerous tissue, shorter T2 values were observed 
within lesions at baseline (83.5 and 80.5 ms) and 6 months (81.5 and 81.9 ms) in the 
placebo and dutasteride arm, respectively. No significant differences for T2W contrast at 
baseline and after 6 months were observed, both in the placebo [0.40 (0.29-0.49) vs 
0.43 (0.25-0.49); p=0.881] and dutasteride arm [0.35 (0.24-0.47) vs 0.37 (0.22-0.44); 
p = 0.668]. There was a significant, positive correlation between the T2Q contrast and 
the T2W contrast values (r=0.786; p<0.001).  
Data conclusion: The exposure to antiandrogen therapy did not significantly influence 
the T2 contrast or the T2 relaxation values in men on active surveillance for prostate 
cancer. 
 
Keywords: Prostatic neoplasms; Active surveillance; Magnetic Resonance Imaging; 







Multiparametric magnetic resonance imaging (mpMRI) combines high-resolution T2-
weighted imaging (T2-WI) sequences with dynamic contrast-enhanced - DCE - and 
diffusion-weighted imaging - DWI -, and/or spectroscopy (1).  Today mpMRI plays a 
pivotal role in the diagnosis and risk stratification of men with prostate cancer (2).  The 
key sequences that drive this process are T2-WI and DWI with DCE providing useful input 
in select cases (3-4). 
 
T2-WI generates a high signal-to-noise ratio and confers high spatial resolution.  These 
attributes permit the depiction of subglandular structures and for the differentiation of 
the zonal anatomy of the prostate (e.g. peripheral/transitional zone, seminal vesicles, 
neurovascular bundles and urethra) (5-6). 
 
The peripheral zone is characterized by high signal intensity on T2-WI, due to its higher 
water content, and cancer is frequently seen as an area of lower signal intensity. 
However, other conditions such as prostatitis, fibrosis, scar tissue, post-biopsy 
hemorrhage may also cause low T2 signal intensity, and result in false positive diagnoses 
(7). The degree of intensity decrease on T2-WI in the peripheral zone has been 
correlated with Gleason score, with higher Gleason scores having lower signal intensities 
(8). 
 
T2-WI is also considered the most important sequence for the detection of cancer in the 
transitional zone according to recent guidelines (9-10), even though the heterogeneous 
appearance of benign prostate hyperplasia nodules in the transitional zone makes 
assessment for cancer challenging in this area (11). 
 
Historically, T2-WI information has been used by radiologists in a qualitative manner and 
imputed into risk models such as Prostate Imaging Reporting and Data System (PI-
RADS) (9). However, quantitative derivatives (T2 relaxation time) can also be generated 
from the T2-WI.  These outputs may be useful in helping to discriminate clinically 
significant cancer from the background signal.   Roebuck and colleagues evaluated T2 
values on a pixel-by-pixel base using Carr-Purcell-Meiboom-Gill (CPMG) quantitative 
imaging, and found that prostate cancer shows a significantly shorter T2 value when 
compared to healthy tissue (12).   
It is known that dutasteride inhibits the enzyme 5 alpha-reductase, which converts 
testosterone to dihydrotestosterone, and is widely used for the treatment of lower 
urinary tract symptoms associated with an enlarged prostate (13). Dutasteride is 
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associated with a reduction of prostate volume, and there is evidence that dutasteride 
may delay the rate of progression in men on active surveillance for prostate cancer (14). 
However, it is not known what effect dutasteride may have on the appearance of 
prostate cancer on T2-WI, and this is a clinically important information since mpMRI is 
gaining popularity as one of the assessment tools in patients on active surveillance.  
In order to further evaluate the role of quantitative T2 outputs we undertook specific 
analyses on the T2-WI and multi-echo CPMG sequences from men recruited into MAPPED 
– a randomized study of dutasteride versus placebo in men with low risk prostate cancer 
on active surveillance, using mpMRI as an endpoint (15). 
Our aim was to measure the T2 relaxation time, a biomarker of tissue pathology, in 




MATERIALS AND METHODS 
This study is a retrospective analysis from a phase II, randomized, double blind, 
prospective clinical trial approved by the Hammersmith & Queen Charlotte’s & Chelsea 
Research Ethics Committee (UK) (09/H0707/84), and the Medicines & Health Regulatory 
Agency and registered on the European Clinical Trials register (EudraCT 2009-102405-
18) (15). The study was sponsored by University College London and GlaxoSmithKline 
(GSK) funded it through an unrestricted grant.  
 
Eligibility criteria and study design 
All men gave their consent to participate in this study and the full protocol has been 
published (15). Between June 2010 and January 2012, 42 men were recruited, and 40 
completed the study. Eligible men had biopsy-proven low-intermediate risk prostate 
cancer and an MR visible lesion  0.2ml on T2-weighted sequences, based on biopsy 
within the preceding two years.  All eligible men met the National Institute for Health and 
Clinical Excellence (NICE 2008) active surveillance criteria for low-intermediate risk 
prostate cancer (up to Gleason 3+4, PSA up to 20 ng/ml and/or clinical stage up to T2c) 
(16). 
All men included in this study did not have any prostate cancer treatment (hormone 
manipulation, prostatic surgery, and treatment with any 5-alpha reductase inhibitor) in 
the previous 12 months. A 3T MR scan including T1- and T2-weighted and DW imaging 
was performed and after review by a study radiologist confirming suitability, men were 
individually randomized (1:1) to daily placebo or dutasteride using block randomization 
with varying block sizes. MpMRI was repeated at 6 months. 
 
MR imaging  
All patients underwent MR imaging on a 3T system (Magnetom Verio, Syngo MR B 17; 
Siemens Healthcare, Erlangen, Germany) and a pelvic phased-array coil. All 
examinations included unenhanced axial, sagittal and coronal turbo spin-echo T2 
weighted imaging, axial DWI (b values of 0, 100, 800 and 1400 s/mm2) with 
reconstruction of the apparent diffusion coefficient (ADC) map and axial T1-weighted 
imaging during intravenous injection of 0.1 mmol/kg of body weight of gadoterate 
meglumine (Dotarem®, Guerbet, Roissy, France) at a rate of 2 mL/s. The protocol was in 
line with standard guidelines (17).  
Quantitative T2 imaging was performed with a multi-echo approach based on the CPMG 
imaging sequence (12). The vendor-supplied CPMG sequence consisted of optimized 180° 
sinc refocusing pulses, with spoiler gradients of constant amplitude applied around each 
refocusing pulse along the frequency-encoding direction (18). The multi-echo CPMG 
protocol was optimized to ensure a good compromise between several parameters; these 
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included the in-plane spatial resolution, the sampling of the T2 relaxation decay, the 
signal-to-noise ratio and the scan time. Protocol optimization was carried out on 3 
healthy volunteers; the CPMG sequence parameters chosen for the quantitative T2 
imaging of the current study are shown in Table 1. 
 
Image analysis 
All mpMRI data were anonymized. Two board-certified radiologists (AK and FG, with 11 
and 4 years of experience in prostate cancer mpMRI interpretation, respectively) 
reviewed the scans in consensus according to PI-RADS v.2 guidelines (9), using 
commercial image viewing software (Osirix ® v. 4.1.2; Geneva, Switzerland). Both 
readers were unaware of treatment allocation and were privy only to the date of the 
scan. To ensure consistency, all scans were reported in chronological order (i.e. first 
baseline, and then 6-month scan).  
All lesions were visible on T2-WI (used as the reference standard) at baseline and after 6 
months, and image quality was adequate in all patients.  
First, the two readers manually traced three regions of interest (ROIs) on the T2-
weighted high-resolution images. The largest lesion (index tumor) was chosen, if multiple 
foci were detected in the same patient. The ROI was copied and pasted in the non-
cancerous peripheral (PZ) and transitional (TZ) zone, in mirror position to the lesion (Fig. 
1) on the same slice. The signal values from this sequence were defined as T2-weighted 
(T2W). 
The three ROIs were then copied and pasted on the multi-echo CPMG sequence. 
Quantitative T2 data analysis of each ROI started with visual inspection of the T2 
relaxation decays. The signal of the first echo was observed to be lower than expected -
at times even lower than the second echo. This is in line with previous observations on 
CPMG data (12, 19). Thus, the signal of the first echo was omitted from the data 
analysis. T2 values were estimated by fitting the signal 𝑆𝑛 obtained at the echo times 
𝑇𝐸𝑛 (n = 2, 3, …, 8) to the mono-exponential decay function 𝑆𝑛 = 𝑆0𝑒
−
𝑇𝐸𝑛
𝑇2⁄  where 𝑆0 is 
a parameter proportional to the tissue proton density and external experimental factors. 
T2 data fitting was performed using MATLAB (MathWorks, Natick, MA, USA). The T2 
values of the lesion, PZ and TZ were determined both at baseline and after 6 months.  
For each patient, we also measured the signal intensity of the lesion (𝑆𝐿) and compared 
it to the signal intensity of presumed non-cancer tissue in mirror position, i.e. (𝑆𝑃𝑍) for 
(𝑆𝐿) in the PZ and (𝑆𝑇𝑍) for (𝑆𝐿) in the TZ on T2-WI. For example, we calculated the T2W 
contrast between a lesion in the PZ and the non-cancerous tissue using the equation: 
T2W contrast = (S𝑃𝑍 – 𝑆𝐿)/S𝑃𝑍. Furthermore, to investigate whether there was a 
correlation between the T2-weighted and the quantitative T2 imaging data, we calculated 
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a ‘synthetic’ contrast using the T2 values obtained from the CPMG data fitting. The 
calculation was as follows: first, we calculated the signal intensity that the lesion (with a 
T2 obtained from quantitative T2 imaging) would yield in the T2-weighted image. This 
was achieved by using the equation S𝐿
𝑠 =  𝑆0𝑒
−𝑇𝐸 𝑇2⁄ , where TE is the echo time (103 
milliseconds) of the T2W image and 
s
 stands for synthetic. We performed the same 
calculation for the signal of the PZ, 𝑆𝑃𝑍
𝑠 . The last step consisted in calculating the 
‘synthetic’ contrast, T2Q contrast = 𝑆𝑃𝑍
𝑠  – S𝐿
𝑠)/S𝑃𝑍
𝑠  , which was obtained by using the 
quantitative T2 data. 
 
Statistical methods 
Clinical and demographic data are reported using descriptive statistics. Continuous 
variables were summarized by their median values and interquartile range (IQR, 1st 
quartile to 3rd quartile); categorical variables were summarized by means of frequencies 
and percentages. 
We carried out the Wilcoxon signed-rank test to compare baseline and 6-month values 
(T2 values and contrast), first in the placebo and then in the dutasteride group. The 
Mann-Whitney U test was applied to investigate the differences between the two groups 
(placebo vs dutasteride). The relationship between T2W and T2Q contrast was assessed 
by means of the Spearman’s correlation coefficient. 
 
P values less than 0.05 were considered to indicate a significant difference. All statistical 





A total of 40 men (median age 65.15 years; range 49-79 years) were eligible for the 
present study. Lesion locations were as follows: 35/40 (87 %) in the PZ [14/35 (40 %) 
left, 1/35 (3 %) midline and 20/35 (57 %) right] and 5/40 (13 %) in the TZ. 
All men had a positive biopsy at entry; specifically, 22/40 (55%) men had Gleason score 
3+3 and 18/40 (45%) had Gleason 3+4. Of note, thirty-seven men of forty men (93%) 
had histological confirmation of the mpMRI lesion contained cancer either at baseline or 
exit. Three men had discordant histology at baseline, one of whom had a negative exit 
biopsy (placebo group) and two who declined the exit biopsy (one placebo, one 
dutasteride).  
There was no difference in PSA values between the placebo and the dutasteride group at 
baseline [6.2 (5.3–7.8) vs 6.4 (5.1-8.8) ng/mL, p = 0.482], respectively. There was a 
significant difference in PSA values between the two arms after 6 months [6.6 (5.6-8) vs 
3.9 (2.2-5.6) ng/mL, p < 0.001]. 
 
Table 2 compares median ROI measurements at baseline and after 6 months. There was 
a significant difference between baseline and 6-month ROI areas in the dutasteride arm 
[0.38 (0.27-0.61) vs 0.27 (0.20-0.53) cm2; p = 0.005]. Table 3 reports the comparison 
between T2 values of lesions and non-cancerous tissues (for PZ and TZ) at baseline and 
after 6 months. There was a significant difference (p < 0.001) between lesions and PZ for 
each arm, both at baseline and after 6 months (Fig. 2). Table 4 reports the comparison 
for T2 values from all ROIs for each of the two arms, at baseline and after 6 months. 
There were no significant differences both for lesions and non-cancerous tissues (PZ and 
TZ). It should be noted that the median values in the PZ for the placebo arm at baseline 
were virtually the same as those after 6 months. The same finding was observed in the 
dutasteride arm. 
 
No significant differences for T2W contrast at baseline and after 6 months were observed, 
both in the placebo [0.40 (0.29-0.49) vs 0.43 (0.25-0.49); p=0.881] and dutasteride 
arm [0.35 (0.24-0.47) vs 0.37 (0.22-0.44); p = 0.668] (Fig. 3). Additionally, there were 
no significant differences in T2W contrast between the placebo and the dutasteride arm 
at baseline [0.40 (0.29-0.49) vs 0.35 (0.24-0.47); p = 0.409] and after 6 months [0.43 
(0.25-0.49) vs 0.37 (0.22-0.44); p=0.372]. 
There was a significant, positive correlation between T2W and T2Q contrast values 





Our previous paper (20) showed a reduction in tumor volume on T2-WI in men on 
dutasteride for 6 months compared to men on placebo. A further paper analyzing the 
DWI (21) has shown a reduction in conspicuity of prostate cancer in men on dutasteride 
for 6 months compared to placebo.  
 
In this paper, we report the analysis of dedicated research sequences, namely 
quantitative T2 imaging, at the same time as the anatomical T2-WI, but not previously 
analyzed. In contrast to the effect on DWI, the T2Q contrast values (quantitative) and 
the T2W contrast (qualitative) appear to be unaffected by exposure to dutasteride. 
 
Quantitative T2 imaging allows for measuring the T2 relaxation time, a biomarker 
sensitive to tissue microenvironment. However, during a standard mpMRI of the 
prostate, only qualitative T2 imaging (with a high signal-to-noise ratio and spatial 
resolution) is performed, to differentiate the zonal anatomy of the gland and the possible 
presence of cancer (9). Cancerous tissue consists of highly compacted cells, and this 
results in a decrease in T2 signal (22). 
 
Although several recent studies have also evaluated the utility of quantitative T2 imaging 
in prostate cancer (12, 23-29), quantitative in vivo T2 mapping is still a challenge due to 
the long scan duration, and therefore this approach is not routinely performed during a 
standard prostate mpMRI scan.  
 
Our retrospective study aimed to fill this gap by analyzing a cohort of men on active 
surveillance exposed to dutasteride as part of the initial trial, who underwent a dedicated 
multi-echo T2 sequence in addition to the standard mpMRI (15). The data acquisition 
protocol was optimized to yield the full volume coverage of the prostate, a good in-plane 
spatial resolution and a detailed sampling of the T2 relaxation decay in order to obtain an 
accurate measurement of the T2 relaxation time.  The data analysis was performed on 
the ROIs, and data fitting was carried out offline with MATLAB. 
 
It is known that antiandrogen therapy affects prostatic tissues, which inevitably affects 
the interpretation of mpMRI studies. The quantitative T2 values are closely related to 
tissue properties and in our study, they were not influenced by dutasteride. 
 
The correlation between the T2W and T2Q contrast provides insight into the results 
obtained from the qualitative and quantitative T2 imaging data. Considerable variability 
 10 
of the contrast in the T2-WI was observed; same consideration applies to quantitative T2 
measurements, where different T2 values were measured in different patients. Does this 
variability in T2-WI contrast and quantitative T2 values originate from measurement 
error, or reflect true inter-individual differences? The correlation found between the 
contrast measured on the T2-weighted images and the “synthetic” contrast calculated 
from the quantitative T2 measurement indicates that the variability could be partly 
explained by inter-individual differences. In other words, in patients with a high lesion 
contrast in the PZ (measured on T2-WI), the T2 values measured by T2Q would have 
yielded T2-weighted images with a high contrast. Similarly, in patients with a low lesion 
contrast in the PZ, the T2 values would have yielded T2-weighted images with a low 
contrast.   
 
Starobinets and colleagues (29) reported no significant differences in contrast on T2-WI 
between untreated and treated men. Similarly, we did not find any difference between 
the two arms, both at baseline and after 6 months of exposure to dutasteride. Following 
our definition of contrast, we could consider this parameter as a surrogate of the 
conspicuity of the lesion on T2-WI. It follows that the use of dutasteride does not seem 
to influence lesion conspicuity on T2-WI (i.e. the lesion is still detectable after 
treatment). This finding is also supported by the significant difference in T2 values from 
quantitative T2 measurements between the lesion and non-cancerous PZ for each arm, 
before and after treatment.  
 
It is known that visible lesions on mpMRI have an increased overall risk of cancer 
progression, so that identifying these lesions is of clinical importance (30). 
Our results confirm that mpMRI can be used for reassessment during active surveillance 
in patients treated with 5-alpha-reductase inhibitors, as these medications do not affect 
signal intensity on quantitative and qualitative T2 imaging, although our previous 
publication (20) suggests that 5-alpha-reductase inhibitors do result in a decrease in 
MRI-visible tumor volume. We agree with the PRECISE (Prostate Cancer Radiological 
Estimation of Change in Sequential Evaluation) recommendations (31) for reporting MRI 
in active surveillance that further studies are necessary to investigate exactly which 
imaging parameters (e.g. tumor volume measurements on T2-WI) would be most 
appropriate to initiate repeat biopsy or indeed treatment. 
 
A number of methodological limitations in our study should be mentioned. First amongst 
these is the relatively small cohort of men. In mitigation, the men were all included in a 
prospective randomized controlled trial and therefore we subject to standardized mpMRI 
and assessment. The study was of relatively short duration for a prostate cancer study 
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and therefore does not reflect the natural history of the condition.  Secondly, some may 
regard the absence of tissue verification by means of radical prostatectomy step section 
pathological processing as a limitation. In this relatively low risk population who had 
elected to enroll in an active surveillance study few would choose to have surgery and 
therefore we would have to deal with missing data.  The use of targeted biopsy - the 
reference test used in this study that could be applied to all men – has been shown to be 
as accurate as 5mm template biopsy (32). It is acknowledged that PZ and TZ tumors are 
scored differently according to PI-RADS v. 2 guidelines (9), and our cohort was 
composed of 35 PZ and 5 TZ tumors. There is some likelihood that dissimilar evaluations 
would have arisen if the number of TZ lesions (more heterogeneous from a histological 
point of view) had been higher.  
 
In conclusion, after this retrospective analysis, we found that T2 relaxation times and T2-
WI were not significantly influenced by the exposure to dutasteride in men on active 
surveillance for prostate cancer. This suggests that the drug may not impair our ability to 
measure tumor volume in active surveillance and longitudinal studies. 
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Table 1. MRI parameters of the Carr-Purcell-Meiboom-Gill (CPMG) sequence for 



























Note – TR = repetition time; ms = milliseconds; TE = echo time; 
mm=millimeters; Hz = Hertz; px = pixel; BW = band-with; FOV: field of view; 
mins = minutes; secs=seconds 
  CPMG  
TR (ms)  3000 
Number of Echoes 8 
TE values (ms) 15, 30, 45, 60, 
75, 90, 105, 120,  
Number of Slices  14  
Slice thickness (mm) 4  
In plane resolution (mm) 1.1 x 1.1 
Interslice Gap (mm) 1 
BW (Hz/px)  352 
Orientation  Axial 
FOV (mm)   165 x 220 
Scan Time (mins:secs) 7:52 
Number of Averages 1 
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Note - Data are medians with interquartile ranges in parentheses. ROI: region of interest. 
 
  
 Placebo Dutasteride 
Baseline  6 months p Baseline 6 months p 
ROI (cm2) 0.46 (0.33-0.62) 0.45 (0.33-0.64) 0.881 0.38 (0.27-0.61) 0.27 (0.20-0.53) 0.005 
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Table 3. T2 values (in milliseconds) for lesions (L) and non-cancerous tissues (PZ and TZ) at baseline and after 6 months for each of the 
two arms. The p-values (Wilcoxon signed-rank test) for T2 comparison between L–PZ and L-TZ are also displayed. 
 
Placebo 
 Lesion Non-cancerous PZ p (L-PZ) Non-cancerous TZ p (L-TZ) 
Baseline 83.5 (70.1-95.8) 133.7 (99.6-152.4) < 0.001 97.7 (84.4-106.0) 0.117 
6 months 81.5 (72.4-100.5) 133.7 (109.5-157.2) < 0.001 96.2 (88.4-103.6) 0.108 
Dutasteride 
 Lesion Non-cancerous PZ p (L-PZ) Non-cancerous TZ p (L-TZ) 
Baseline 80.5 (74.2-89.5) 107.2 (97.1-126.6) <0.001 88.1 (75.4-94.6) 0.113 
6 months 81.9 (72.4-85.8) 107.9 (95.9-129.5) <0.001 83.2 (76.5-90.2) 0.351 
 
 






Table 4. T2 values (in milliseconds) for each of the two arms included in the study at baseline and after 6 months. The p-values 
(Wilcoxon signed-rank test) for T2 comparison between baseline and 6-month mpMRI are also displayed. 
 
 
Note - Data are medians with interquartile ranges in parentheses. PZ: peripheral zone; TZ: transition zone 
 
 Placebo 
Baseline  6 months p 
Lesion 83.5 (70.1-95.8) 81.5 (72.4-100.5) 0.179 
Non-cancerous PZ 133.7 (99.6-152.4) 133.7 (109.5-157.2) 0.654 
Non-cancerous TZ 97.7 (84.4-106.0) 96.2 (88.4-103.6) 0.332 
Dutasteride 
Baseline  6 months p 
80.5 (74.2-89.5) 81.9 (72.4-85.8) 0.681 
107.2 (97.1-126.6) 107.9 (95.9-129.5) 0.794 
88.1 (75.4-94.6) 83.2 (76.5-90.2) 0.502 
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Figure 1 
MR images of the prostate of a 69-year-old man with a PSA of 5.83 ng/ml and a Gleason 
3+4 tumor in the mid-right peripheral zone at entry biopsy. The region of interest (ROI) 
for quantitative T2 analysis is here illustrated. Three ROIs (lesion, non-cancerous 
peripheral and transitional zones) were drawn on the high-resolution T2 image. These 
ROIs were then copied and pasted on the multi-echo images. 
 
Figure 2 
Box and whisker plots showing T2 values from the three ROIs for each arm, both at 
baseline and after 6 months. [Bottom of box = 25th percentile, center line = median, top 
of box = 75th percentile, whiskers = 10th and 90th percentiles, ° = outliers (between 1.5 
and 3 interquartile ranges), * = extreme outliers (more than 3 three interquartile 
ranges)]. PZ: peripheral zone; TZ: transition zone 
 
Figure 3 
Box and whisker plots showing T2-weighted contrast values for each arm, both at 
baseline and after 6 months. [Bottom of box = 25th percentile, center line = median, top 
of box = 75th percentile, whiskers = 10th and 90th percentiles]. 
 
Figure 4 
Scatter plot of contrast from high-resolution T2-weighted (T2W) and quantitative T2 
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